Your browser doesn't support javascript.
loading
Therapeutic Implications of Oncogenic Missense HER2 (ERBB2) Mutations in Gastric Adenocarcinoma.
King, Daniel A; Weiel, Julianna J; Reyes, Rochelle; Mills, Meredith; Itchon, Antonita; Fisher, George A; Ford, James M; Suarez, Carlos J.
Affiliation
  • King DA; Northwell Health Cancer Institute and Feinstein Institute of Research, Lake Success, NY.
  • Weiel JJ; Department of Pathology, Stanford University School of Medicine, Stanford, CA.
  • Reyes R; Department of Pathology, Billings Clinic, Billings, MT.
  • Mills M; Early Drug Development Group, Stanford Cancer Institute, Stanford, CA.
  • Itchon A; Division of Oncology, Department of Internal Medicine, Stanford University, Stanford, CA.
  • Fisher GA; Division of Oncology, Department of Internal Medicine, Stanford University, Stanford, CA.
  • Ford JM; Division of Oncology, Department of Internal Medicine, Stanford University, Stanford, CA.
  • Suarez CJ; Division of Oncology, Department of Internal Medicine, Stanford University, Stanford, CA.
JCO Precis Oncol ; 7: e2200093, 2023 02.
Article in En | MEDLINE | ID: mdl-36787506
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Adenocarcinoma Limits: Humans Language: En Journal: JCO Precis Oncol Year: 2023 Document type: Article Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Adenocarcinoma Limits: Humans Language: En Journal: JCO Precis Oncol Year: 2023 Document type: Article Country of publication: United States